IL-10-Expressing MSCs for Stable Transplant Engraftment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Mesenchymal stem cells (MSCs) face challenges with unstable post-transplantation survival and engraftment rates, leading to graft failure and difficulty in maintaining therapeutic gene expression over a long period.
Innovation Solution
Overexpressing interleukin-10 (IL-10) in MSCs using a plasmid or virus vector to enhance survival and engraftment rates, and administering MSCs with an immunogen before transplantation to induce acquired immunological tolerance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MSCs are transplanted directly without modification, then the transplantation process is simple, but the post-transplantation survival rate and engraftment rate are unstable and low
Solution Approach 1:
The patent modifies the biological parameters of MSCs by introducing IL-10 gene expression, which changes the cellular phenotype to enhance survival and engraftment capabilities. This parameter change transforms the cells from having unstable survival rates to exhibiting improved reliability without requiring complex structural modifications.
Solution Approach 2:
The IL-10 cytokine acts as an intermediary substance that mediates between the transplanted MSCs and the host immune system. By overexpressing IL-10, the cells gain protective immunosuppressive effects that improve their survival and engraftment without direct complex engineering of the cells themselves.
2Duration of action of moving object
If MSCs are transplanted without gene modification, then the procedure is straightforward, but therapeutic gene expression cannot be maintained over a long period
Solution Approach 1:
The patent applies preliminary action by introducing the IL-10 gene into MSCs before transplantation. This pre-modification ensures that the cells possess the desired therapeutic gene expression capability from the outset, enabling long-term maintenance of gene expression rather than requiring repeated treatments or complex post-transplantation gene delivery systems.
Solution Approach 2:
The patent extracts the key functional requirement (IL-10 gene expression) and isolates it as the core modification needed for long-term therapeutic effect. By focusing on this single critical gene rather than attempting to maintain multiple therapeutic genes, the solution achieves durable expression with relatively simple gene delivery mechanisms.
3Reliability
If high doses of immunosuppressants are used to prevent rejection, then rejection is suppressed, but strong systemic immunosuppression and adverse reactions occur
Solution Approach 1:
The patent converts the harmful effect of immune rejection into a beneficial outcome by using the transplanted MSCs themselves to produce IL-10, which then suppresses the immune response. Instead of using external immunosuppressants that cause systemic harm, the therapy harnesses the cells' own modified capability to create localized immunosuppression that protects the graft without causing adverse reactions.
Solution Approach 2:
The modified MSCs serve themselves by autonomously producing IL-10 cytokine that protects them from immune rejection. The cells do not require external immunosuppressive drugs; instead, they self-generate the protective factor needed for their survival and engraftment, eliminating the need for harmful systemic immunosuppression.
Data Source
AI summary
It is intended to provide MSCs for transplantation that have an improved post-transplantation cell survival rate and engraftment rate and are highly safe with fewer adverse reactions, and a method for conveniently producing MSCs for transplantation having a high cell survival rate and engraftment rate. As means therefor, the present invention provides a stem cell for transplantation comprising an MSC capable of overexpressing IL-10.